NO20052379L - New antitumoral compounds - Google Patents

New antitumoral compounds

Info

Publication number
NO20052379L
NO20052379L NO20052379A NO20052379A NO20052379L NO 20052379 L NO20052379 L NO 20052379L NO 20052379 A NO20052379 A NO 20052379A NO 20052379 A NO20052379 A NO 20052379A NO 20052379 L NO20052379 L NO 20052379L
Authority
NO
Norway
Prior art keywords
antitumoral compounds
new antitumoral
new
compounds
kahalalide
Prior art date
Application number
NO20052379A
Other languages
Norwegian (no)
Other versions
NO20052379D0 (en
NO333448B1 (en
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Pablo Manuel Aviles Marin
Maria Del Carmen Cue Marchante
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of NO20052379D0 publication Critical patent/NO20052379D0/en
Publication of NO20052379L publication Critical patent/NO20052379L/en
Publication of NO333448B1 publication Critical patent/NO333448B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
NO20052379A 2002-10-18 2005-05-13 New 4-methylhexanoic acid kahalalide F compounds, methods for their preparation, their use for the preparation of a drug preferably for the treatment of cancer, pharmaceutical compositions comprising the compounds, and a kit containing a pharmaceutical composition comprising the compounds. NO333448B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (3)

Publication Number Publication Date
NO20052379D0 NO20052379D0 (en) 2005-05-13
NO20052379L true NO20052379L (en) 2005-07-15
NO333448B1 NO333448B1 (en) 2013-06-10

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052379A NO333448B1 (en) 2002-10-18 2005-05-13 New 4-methylhexanoic acid kahalalide F compounds, methods for their preparation, their use for the preparation of a drug preferably for the treatment of cancer, pharmaceutical compositions comprising the compounds, and a kit containing a pharmaceutical composition comprising the compounds.

Country Status (12)

Country Link
KR (2) KR20110114690A (en)
AT (1) ATE490975T1 (en)
AU (1) AU2003285911B2 (en)
CY (1) CY1111319T1 (en)
DE (1) DE60335292D1 (en)
DK (1) DK1572726T3 (en)
HK (1) HK1082261A1 (en)
IL (1) IL167724A (en)
NO (1) NO333448B1 (en)
PL (1) PL209129B1 (en)
PT (1) PT1572726E (en)
SI (1) SI1572726T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
HUP0600031A3 (en) * 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
HK1082261A1 (en) 2006-06-02
PL209129B1 (en) 2011-07-29
KR20050070056A (en) 2005-07-05
ATE490975T1 (en) 2010-12-15
SI1572726T1 (en) 2011-04-29
DE60335292D1 (en) 2011-01-20
PT1572726E (en) 2011-02-14
NO20052379D0 (en) 2005-05-13
AU2003285911A1 (en) 2004-05-04
IL167724A (en) 2012-01-31
AU2003285911B2 (en) 2009-11-19
KR20110114690A (en) 2011-10-19
NO333448B1 (en) 2013-06-10
DK1572726T3 (en) 2011-03-28
PL377056A1 (en) 2006-01-23
CY1111319T1 (en) 2015-08-05
KR101149095B1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
UY28258A1 (en) THERAPEUTIC TREATMENT
NO20055741L (en) New chemical compounds
EA200400971A1 (en) Fluorine-substituted cycloalkanoylindoles, compositions containing such compounds, and methods of treatment
CY1112743T1 (en) STEERIFIOMETRICULARLY enriched 3-Aminocarbonyl bicyclic pyrimidinodiamine compounds and their uses
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
BRPI0418251A (en) phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
EA200201214A1 (en) SUBSTITUTED THYOCETAMIDES
MXPA04003796A (en) Substituted thioacetamides.
CL2007002384A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of psoriasis.
BR0315644A (en) Piperazinyl and diazapanyl benzamides and benzothioamides
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
ATE486915T1 (en) AZEOTROP-LIKE COMPOSITION OF 1,2-DICHLORO-3,3,3-TRIFLUOROPROPENE AND HYDROGEN FLUORIDE
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
BR0209541A (en) Use of 2-phenyl-substituted imidazotriazinones
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
DE60101559D1 (en) USE OF COMT INHIBITORS AS ANALGETICS
EP1667976A4 (en) Isoquinolinone potassium channel inhibitors
BRPI0511125A (en) Uses of 5,6,7-trihydroxyheptanoic acid and its analogues
HUP0402165A2 (en) Non-neurotoxic plasminogen activating factors for treating stroke
DE60316128D1 (en) N-sulfonylurea APOPTOSIS PROMOTERS
NO20052379L (en) New antitumoral compounds
EA200200948A1 (en) TREATMENT OF PSORIASIS
DE602004019541D1 (en) CYCLOALKYLÄBÜ CONDENSED INDOLE

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees